Search

Updates on two of our stocks that reported earnings, plus updates on six other holdings.

Sinclair Broadcast Group is a little-known mid-cap stock that has risen 350% in the last five years. More big gains could be ahead after a recent buyout.

BioLife (BLFS) reported Q4 results yesterday after the close that surpassed revenue expectations. Revenue was up 77.5% to $14.7 million (beating by $1.2 million) while adjusted EPS of -$0.01 was in-line. For the full-year 2020 revenue was up 76% to $48.1 million, driven largely by Media products, which grew by 32% to $31 million.

Our interest in oil and natural gas exploration and production (E&P) companies has been warming up lately. Many of these stocks are beaten down, yet oil prices have remained resilient, leaving producers like ConocoPhillips meaningfully undervalued.

We’re enjoying better-than-expected results from reporting companies this week. Here’s my quick take on three Cabot Small-Cap Confidential positions that have recently reported.

Today’s note includes earnings updates, ratings changes, the podcast and the Catalyst Report.

Cabot Benjamin Graham Value Investor Analyst Roy Ward tells The Money Show what he likes about Xerox and Walgreen’s.

There are some potential signs that signal that illness has set into your stock. Here are the ways to recognize the bad and the ugly stocks.

I had already sensed an opportunity in big oil over the weekend and wrote an article that will appear on the Cabot website in the coming days.

This small-cap stock has been a favorite of mine for years and remains a deeply undervalued pure play on private equity growth.

Small caps frequently trade at a discount to larger peers, and this head-to-head look at two peers in the same sector should show you why small caps are the better value.

The new bull market is certainly a rising tide, but it isn’t lifting all boats equally yet. Here are three undervalued micro-cap stocks being ignored by the market.

The 2-year bear market in biotech stocks has some trading for less than their cash on hand. Here are 3 I like.

When looking at small-cap stocks vs. large-cap stocks you’ll find that small-cap stocks are undervalued. Here’s a case study to demonstrate (and two stocks I like).

In the midst of a multiyear bear market for biotechs there’s still opportunity, like these 3 stocks trading for less than the cash on their balance sheets.

Investors bullish on Bitcoin have more than one way to play a surge in the token, and this angle offers a potential arbitrage opportunity.

The strength of U.S. equities, coupled with the rise in global conflict, has been propelling defense stocks higher, and this little-known defense contractor is on a tear.